Recombinant Human IFNA4 protein

中文名： 干扰素α-4(IFNA4)重组蛋白
别名： IFNA4；Interferon alpha-4

货号: PA1000-4028

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>97%SDS-PAGE.
种属	Human
靶点	IFNA4
Uniprot No	P05014
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	23-189aa
氨基酸序列	GCDLPQTHSL GNRRALILLA QMGRISHFSC LKDRHDFGFP EEEFDGHQFQ KAQAISVLHE MIQQTFNLFS TEDSSAAWEQ SLLEKFSTEL YQQLNDLEAC VIQEVGVEET PLMNEDSILA VRKYFQRITL YLTEKKYSPC AWEVVRAEIM RSLSFSTNLQ KRLRRKD
预测分子量	46 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于IFNA4重组蛋白的3篇代表性文献的简要信息(基于公开研究领域知识模拟，非真实文献)：

1. **《Expression and functional characterization of recombinant human interferon alpha 4 (IFNA4) in mammalian cells》**

- 作者：Li, Y., et al.

- 摘要：研究利用哺乳动物表达系统(如HEK293细胞)重组表达IFNA4蛋白，验证其纯化后的生物活性，包括抗病毒效应及对STAT信号通路的激活能力。

2. **《Structural insights into the distinct receptor binding of IFNA4 compared to other type I interferons》**

- 作者：Smith, J.R., et al.

- 摘要：通过X射线晶体学解析IFNA4重组蛋白的三维结构，揭示其与干扰素受体IFNAR的结合模式差异，解释其相较于其他IFNA亚型可能存在的独特功能机制。

3. **《IFNA4 recombinant protein enhances dendritic cell-mediated T cell activation in chronic viral infection models》**

- 作者：Wang, H., et al.

- 摘要：在慢性病毒感染模型中，重组IFNA4被证明可增强树突状细胞的抗原呈递功能，促进CD8+ T细胞活化，提示其作为免疫调节剂的潜在治疗价值。

**注**：以上文献为示例性内容，实际研究中请通过PubMed或Web of Science等平台以“IFNA4 recombinant”或“interferon alpha 4 expression”为关键词检索最新论文。

背景信息

Interferon alpha-4 (IFNA4) is a member of the type I interferon family, a group of cytokines critical for innate immunity against viral infections and immune regulation. Encoded by the *IFNA4* gene located on human chromosome 9p21.3. IFNA4 shares structural homology with other interferon-alpha subtypes, featuring a conserved helical bundle structure that binds to the interferon-α/β receptor (IFNAR). This interaction triggers JAK-STAT signaling pathways, inducing the expression of interferon-stimulated genes (ISGs) with antiviral, antiproliferative, and immunomodulatory functions.

Recombinant IFNA4 is produced using biotechnological platforms, such as *E. coli* or mammalian cell systems, enabling large-scale synthesis for research and therapeutic applications. Unlike natural IFNA4. which is secreted by virus-infected cells or plasmacytoid dendritic cells, the recombinant form offers standardized purity and activity, bypassing challenges associated with endogenous protein variability. Its production often involves codon optimization, fusion tags for solubility, and chromatographic purification to ensure bioactivity.

Although less studied than IFN-alpha-2 or IFN-alpha-1. IFNA4 has unique antiviral properties and may exhibit subtype-specific roles in immune responses. Research explores its potential in treating viral infections (e.g., hepatitis B/C), cancers (e.g., melanoma, leukemia), and autoimmune disorders, either alone or as an adjuvant. Recent studies also investigate its synergy with checkpoint inhibitors in immunotherapy. However, clinical adoption remains limited compared to other interferons, partly due to subtype-specific signaling nuances and side effects like flu-like symptoms. Ongoing work aims to optimize its therapeutic window through pegylation or targeted delivery systems.